The treatment of juvenile arthritis

Abstract

Until recently, two different classification systems for juvenile arthritis (JA) were utilised, each with its own terminology and subclassification (Table 1) [1]. It has been recognised that particularly within the polyarticular and pauci-articular groups, many distinct subsets exist each with a different prognosis. As a result, a new classification system for JA has been developed (Table 2) [2]. It is hoped that this will allow more accurate assessment of incidence and aetiology of the various subtypes in future generations and in time will allow therapy to be targeted at those most likely to achieve benefit. Since there is a new classification system for JA, the vast majority of published clinical studies were performed using the old classification system. For the purposes of this review, unless otherwise stated, the American College of Rheumatology classification will be used. This is outlined in Table 1 with clinical features of the major subtypes described in Table 3. This review will cover current best practice and discuss future directions for research using the recent advances in the treatment of rheumatoid arthritis (RA) as a model.

• disease modifying drugs
• etanercept
• glucocorticoids
• juvenile arthritis
• non-steroidal anti-inflammatory drugs